Keywords: UK, NICE, Roche, Tarceva, NSCLC, Nvartis, Afinitor, Kidneh cancer

UK’s NICE not to recommend Roche’s Tarceva for NSCLC and Novartis’ Afinitor rejected for kidney cancer, with both drugmakers to appeal

Article | 26 November 2010

Print This

In what is a further disappointment for Swiss drug major Roche (ROG: VX), the UK’s drug watchdog the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in